Early Detection of Broken Hearts in Cancer Patients

Completed

Conditions studied: Cardiotoxicity

In brief

The early detection of BVZ or Sunitinib mediated cardiotoxicity using cardiac biomarkers and novel Transthoracic Echocardiogram (TTE) techniques may allow one to adjust treatment and/or administer prophylactic cardioprotective agents, prior to the development of irreversible cardiac dysfunction. We hypothesize that cardiac biomarkers, TVI/strain-derived indices will be able to accurately detect subtle cardiac injury at a time when conventional Left Ventricular Ejection Fraction (LVEF) remains normal in BVZ or Sunitinib mediated cardiotoxicity. Additionally, we hypothesize that Endothelial Function Test (EndoPAT) testing can detect early BVZ or Sunitinib mediated endothelial dysfunction.

Key facts

Study ID

NCT02086695

Run by

Mayo Clinic

People needed

43

Starts

2013-06-01

Expected to finish

2015-09-01

Last updated by the study team

2016-01-29

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with advanced cancer
• Treatment plan includes BVZ ,Sunitinib, or Pazopanib
• Ages 18 - 90 years old -
• Exclusion Criteria: Left Ventricular EF < 50%

Where it is running

• Mayo Clinic — Rochester, Minnesota, United States
• St. Boniface General Hospital — Winnipeg, Manitoba, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.